Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005787 · ClinicalTrials.gov registry record · Phase 1
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00005787 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 3 participants.
The verdict
NCT00005787, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. Treating the peripheral stem cells in the laboratory may improve the effectiveness of the transplant. PURPOSE: Phase I trial to study the effectiveness of peripheral stem cell transplantation in patients who have relapsed or refractory non-Hodgkin's lymphoma and who will be treated with high-dose chemotherapy.
Interventions
- BIOLOGICAL filgrastim
- BIOLOGICAL epoetin alfa
- BIOLOGICAL sargramostim
- BIOLOGICAL recombinant flt3 ligand
- BIOLOGICAL recombinant interleukin-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 1999-09 |
| Est. Completion | 2002-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005787
The ClinicalTrials.gov registry entry for NCT00005787 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which filgrastim is the first listed.
NCT00005787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005787 about?
NCT00005787 is a clinical study titled "Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma". RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. Treating the peripheral stem cells in the laboratory may improve the effectiveness of the transplant. PURPOSE: Phase I trial to study the effectiveness ...
What is the current status of trial NCT00005787?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 1999-09. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00005787?
The interventions under investigation include: filgrastim (BIOLOGICAL), epoetin alfa (BIOLOGICAL), sargramostim (BIOLOGICAL), recombinant flt3 ligand (BIOLOGICAL), recombinant interleukin-3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005787?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.